EP0613007A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Pharmaceutical screens and antibodies
Assignee: Athena Neurosciences Inc
•
Filing: 1994-02-18
•
Granted: —
•
Expires: 2014-02-18
Abstract
Abstract This invention describes a series of assays useful in evaluating the efficacy of agents which inhibit the neurotoxic effects of β-amyloid peptide. These assays employ β-amyloid peptide which is in a predominantly β-sheet conformation. This invention also encompasses antibodies having a specificity for β-amyloid peptide which is predominantly in a β-sheet conformation as well as pharmaceutic formulations containing these antibodies. These antibodies show poor reactivity with β-amyloid peptide which has a great deal of random coil or α-helix secondary structure.
Inventors
- 👤 Gerald Wayne Becker
- 👤 David Nettleship Brems
- 👤 Michael Owen Chaney
- 👤 Patrick Cornelious May
- 👤 Russel Eugene Rydel
- 👤 Linda Karen Simmons
- 👤 Kevin James Tomaselli
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-24 16:00
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/68; G01N33/6893; G01N33/6896; C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4711
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
64 words
A method for assaying for agents which inhibit the neurotoxicity of β-amyloid peptide which comprises: a. causing a sample of purified β-amyloid peptide to adopt a predominantly β-sheet conformation; b. incubating potential inhibitors of neurotoxicity with the β-amyloid peptide in β-sheet conformation; c. measuring the neurotoxic properties of each β-amyloid peptide/potential inhibitor mixture; and d. detecting reduction in the neurotoxicity relative to a control.
Claim 2
Dependent Claim
19 words
A method as claimed in Claim 1 wherein said β-amyloid peptide has adopted 80% of its potential β-sheet conformation.
Claim 3
Independent Claim
89 words
A method for assaying for agents which inhibit the neurotoxicity of β-amyloid peptide which comprises: a. causing a sample of purified β-amyloid peptide to adopt a predominantly non β-sheet conformation; b. incubating potential inhibitors of neurotoxicity with the β-amyloid peptide in non β-sheet conformation; c. manipulating the β-amyloid peptide in such a way that β-amyloid peptide without the potential inhibitor of neurotoxicity adopts a predominantly β-sheet conformation. d. measuring the neurotoxic properties of each β-amyloid peptide/potential inhibitor mixture; and e. detecting reduction in the neurotoxicity relative to a control.
Claim 4
Dependent Claim
16 words
A method as claimed in Claim 5 wherein said manipulation step is aging of the peptide.
Claim 5
Dependent Claim
26 words
A method as claimed in Claim 3 wherein said β-amyloid peptide in predominantly non β-sheet conformation has adopted less than 50% of its potential β-sheet conformation.
Claim 6
Independent Claim
104 words
A method for assaying for agents which inhibit the neurotoxicity of β-amyloid peptide which comprises: a. allowing a sample of purified β-amyloid peptide to adopt a predominantly β-sheet conformation; b. securing the purified β-amyloid peptide in the predominantly β-sheet conformation to a support; c. incubating with the β-amyloid peptide an antibody which diminishes the neurotoxicity of β-amyloid peptide which is in a predominantly β-sheet conformation; d. incubating with the β-amyloid peptide/antibody mixture a potential inhibitor of neurotoxicity; e. subsequently measuring the amount of unbound antibody in the supernatant; f. determining increase in the amount of unbound antibody in the supernatant relative to a control.
Claim 7
Dependent Claim
24 words
A conformationally-specific antibody which comprises an antibody having high affinity for β-amyloid peptide only when said β-amyloid peptide is in a predominantly β-sheet conformation.
Claim 8
Dependent Claim
14 words
An antibody as claimed in Claim 7 wherein said antibody is a monoclonal antibody.
Claim 9
Dependent Claim
22 words
A method of diagnosing Alzheimer's disease in a mammal which comprises administering to a mammal an antibody as claimed in Claim 7.
Claim 10
Dependent Claim
27 words
A conformationally-specific antibody which comprises an antibody having high affinity for β-amyloid peptide only when said β-amyloid peptide is in a predominantly random coil or α-helix conformation.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.